Our Pricing

Mysimba & Orlistat Together - Private Prescription UK

Published on: June 03, 2026

Many patients ask whether mysimba and orlistat together uk prescription is a safe and effective approach to weight management. At Cured Pharmacy, our UK-registered prescribers assess combination treatment protocols on an individual basis, considering your medical history, current medications, and weight loss goals. While both medications work through different mechanisms, combining them requires careful clinical evaluation to ensure safety and optimise outcomes.

Understanding Mysimba and Orlistat: Different Mechanisms of Action

Mysimba contains naltrexone and bupropion, two active ingredients that work centrally on the brain's appetite regulation centres to reduce food cravings and increase feelings of fullness [1]. Clinical trials demonstrate that Mysimba can help patients achieve an average weight loss of 5-10% of initial body weight when combined with lifestyle modifications [1].

Orlistat, by contrast, works peripherally in the digestive system by blocking approximately 30% of dietary fat absorption [2]. Licensed in the UK at both 60mg (available over-the-counter) and 120mg (prescription-only) strengths, Orlistat prevents fat-digesting enzymes from breaking down triglycerides in the intestine [2]. Because these medications target completely different pathways—one neurological, one gastrointestinal—they theoretically could complement each other without direct pharmacological interaction.

Can You Take Mysimba and Orlistat Together Safely?

From a pharmacological perspective, there are no known direct drug-drug interactions between naltrexone/bupropion (Mysimba) and orlistat. The medications are metabolised through different hepatic pathways and do not compete for the same enzyme systems [3]. However, this does not automatically mean combination therapy is appropriate for every patient.

UK prescribers must consider several clinical factors before approving dual treatment. Mysimba carries specific contraindications including uncontrolled hypertension, seizure disorders, and concurrent use of opioids or MAO inhibitors [1]. Orlistat requires careful monitoring in patients with chronic malabsorption syndromes or cholestasis [2]. The decision to combine these treatments depends on your complete medical profile, current medications, and whether you've already trialled single-agent therapy.

At Cured Pharmacy, our clinical team evaluates combination requests individually. Most prescribers prefer a sequential approach—starting with one medication, assessing response over 12-16 weeks, then considering addition of a second agent if weight loss plateaus or proves insufficient. This staged protocol allows better identification of which medication contributes most to your results and helps isolate any adverse effects.

Clinical Scenarios Where Combination May Be Considered

Combination therapy might be discussed for patients who have achieved partial response with Mysimba alone but continue to consume high-fat diets, as Orlistat specifically targets dietary fat absorption. Conversely, patients stable on Orlistat who struggle with persistent cravings and appetite control might benefit from adding Mysimba's central appetite suppression. Any such approach requires ongoing monitoring by your prescriber and regular review appointments to assess efficacy and tolerability.

Managing Side Effects with Mysimba and Orlistat Combination

Each medication carries its own side effect profile, and combining treatments means you may experience adverse effects from either or both agents. Mysimba commonly causes nausea, constipation, headache, and dizziness, particularly during the initial titration phase [1]. These neurological and gastrointestinal effects typically diminish after the first 4-6 weeks as your body adjusts to the medication.

Orlistat's side effects are predominantly gastrointestinal and directly related to its mechanism of blocking fat absorption. Patients frequently report oily stools, increased bowel frequency, faecal urgency, and flatulence with oily discharge [2]. These effects are most pronounced when consuming meals with fat content exceeding 15g per meal. Adherence to a reduced-fat diet (less than 30% of calories from fat) significantly minimises these symptoms.

When taking both medications together, the gastrointestinal burden may be compounded. Mysimba's tendency to cause nausea combined with Orlistat's digestive effects can prove challenging for some patients. Your prescriber may recommend starting one medication, establishing tolerability, then introducing the second agent gradually. Ensuring adequate hydration, maintaining a balanced lower-fat diet, and taking a multivitamin supplement (at least 2 hours before or after Orlistat) helps manage the combined side effect profile [2].

Mysimba and Orlistat Together: What Clinical Evidence Shows

Currently, there are no large-scale randomised controlled trials specifically evaluating the efficacy and safety of combining Mysimba with Orlistat for weight management. Most clinical evidence examines each medication as monotherapy alongside lifestyle intervention [1][2]. The COR-I and COR-II trials established Mysimba's efficacy profile, whilst the XENDOS study and subsequent trials demonstrated Orlistat's long-term weight maintenance benefits [2][4].

In clinical practice, some prescribers have used combination approaches off-label for carefully selected patients, but this remains outside standard UK prescribing guidelines. NICE guidance on obesity management does not specifically address combination pharmacotherapy with these two agents [4]. Without robust trial data on combined efficacy, additive benefits remain theoretical rather than evidence-based.

The absence of interaction studies also means we lack safety data on long-term combined use. Most UK prescribers therefore adopt a conservative approach, reserving combination therapy for exceptional cases where monotherapy has been insufficient and the patient demonstrates excellent medication adherence and tolerability to both agents individually.

Alternative Combination Approaches

For patients seeking enhanced weight loss outcomes, newer GLP-1 receptor agonists such as semaglutide (Wegovy) or tirzepatide (Mounjaro) may offer superior efficacy compared to older combination approaches. Clinical trials show average weight reductions of 15-22.5% with these injectable treatments [5], significantly exceeding the combined theoretical benefits of Mysimba plus Orlistat. Your prescriber can discuss whether transitioning to a more potent single-agent therapy might better serve your weight loss goals.

Getting a Private Prescription for Mysimba and Orlistat at Cured Pharmacy

All prescription weight loss medications available through Cured Pharmacy require completion of a clinical assessment by a UK-registered prescriber. Our online consultation takes under 3 minutes and covers your medical history, current medications, previous weight loss attempts, and treatment goals. This information allows our clinical team to determine whether single-agent or combination therapy is appropriate for your individual circumstances.

Mysimba is available from £135.00 for a one-month supply, whilst Orlistat starts from £135.00, with branded Xenical from £135.00. If your prescriber approves combination therapy, you'll receive both medications with clear dosing instructions and guidance on dietary modifications to optimise results and minimise side effects. All prescriptions are dispensed by our UK-registered pharmacy (GPhC 9012511) under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073).

We provide discreet packaging and transparent pricing—you'll see the full cost before completing your consultation, with no hidden fees. Our clinical team remains available for follow-up questions, and we recommend booking review consultations every 4-8 weeks to monitor your progress, adjust dosing if needed, and ensure ongoing treatment safety.

Lifestyle Modifications Essential for Combined Treatment Success

Neither Mysimba nor Orlistat works effectively without concurrent lifestyle changes. UK prescribing guidelines emphasise that pharmacotherapy should complement—not replace—dietary modification and increased physical activity [4]. For patients taking both medications, dietary planning becomes particularly important to manage Orlistat's fat-related side effects whilst ensuring adequate nutrition.

A structured eating plan with 25-30% of calories from fat, distributed evenly across three main meals, helps optimise Orlistat's efficacy whilst minimising gastrointestinal symptoms [2]. Mysimba's appetite-suppressing effects may naturally reduce portion sizes and snacking frequency, but patients should ensure they're still consuming adequate protein (1.2-1.6g per kg body weight) to preserve lean muscle mass during weight loss.

Regular physical activity enhances the neurochemical effects of Mysimba and increases overall energy expenditure, complementing Orlistat's reduction in calorie absorption. UK guidelines recommend at least 150 minutes of moderate-intensity activity weekly, progressing to 300 minutes for weight loss maintenance [4]. Combining cardiovascular exercise with resistance training helps preserve metabolic rate as body weight decreases. Your prescriber can provide personalised lifestyle recommendations tailored to your current fitness level and any physical limitations.

Monitoring and Long-Term Management

Successful weight management requires ongoing monitoring and treatment adjustment. Most prescribers assess treatment response at 12-16 weeks—if you haven't achieved at least 5% weight loss by this point, continuing the same regimen is unlikely to produce meaningful results [4]. Regular blood pressure monitoring is essential for patients on Mysimba, whilst those taking Orlistat should have periodic assessment of fat-soluble vitamin levels, particularly vitamins A, D, E, and K [2]. At Cured Pharmacy, we encourage patients to maintain regular contact with our clinical team to ensure your treatment protocol remains safe, effective, and aligned with your evolving health needs.

Scientific References

1. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
2. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mysimba 8mg/90mg prolonged-release tablets. MHRA. Retrieved from https://www.gov.uk/ [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. Retrieved from https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.